NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|575402983|ref|NP_001276392|]
View 

neprilysin [Mus musculus]

Protein Classification

M13 family metallopeptidase( domain architecture ID 10171382)

M13 family metallopeptidase similar to neutral endopeptidase (neprilysin), which degrades and inactivates bioactive peptides, and to endothelin-converting enzyme, which catalyzes the hydrolysis of the bond between Trp-21 and Val-22 in big endothelin to form endothelin 1

EC:  3.4.24.-
MEROPS:  M13
SCOP:  3001975

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M13 cd08662
Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of ...
77-748 0e+00

Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of metallopeptidases includes neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11), endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), erythrocyte surface antigen KELL (ECE-3), phosphate-regulating gene on the X chromosome (PHEX), soluble secreted endopeptidase (SEP), and damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE). Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the active site's S2' subsite allowing substrate specificity. NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P, enkephalins, cholecystokinin, neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD). ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyzes bradykinin, substance P, neurotensin, and Abeta. Endothelin-1 overproduction has been implicated in various diseases including stroke, asthma, hypertension, and cardiac and renal failure. Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A. PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets. ECEL1 is a brain metalloprotease which plays a critical role in the nervous regulation of the respiratory system, while DINE is abundantly expressed in the hypothalamus and its expression responds to nerve injury. A majority of these M13 proteases are prime therapeutic targets for selective inhibition.


:

Pssm-ID: 341056 [Multi-domain]  Cd Length: 642  Bit Score: 780.01  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  77 VEPCTDFFKYACGGWLKRNVIPETSSRYSNFDILRDELEVILKDVLQEP--KTEDIVAVQKAKTLYRSCINESAIDSRGG 154
Cdd:cd08662    1 VDPCDDFYQYACGNWLKNHPIPADKSSWGSFSELQDRNEEQLREILEEAasSAADSSAEQKAKDFYKSCMDEEAIEKLGL 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 155 QPLLKLLPDIYGWPVASDNWDQTYgtswtaeksiAQLNSKYGKKVLINFFVGTDDKNSTQHIIHFDQPRLGLPSRDYYEc 234
Cdd:cd08662   81 KPLKPLLDKIGGLPSLDDLAAELL----------LALLRRLGVSLLFGLGVSPDPKNSSRNILYLGQPGLGLPDRDYYL- 149
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 235 TGIYKEACTAYVDFMISVARLirqeqsLPIDENQLSLEMNKVMELEKEIANATTKPEDRNDPMLLYNKMTLAKLQNNFSl 314
Cdd:cd08662  150 DEENAEIREAYKKYIAKLLEL------LGADEEEAEKLAEDVLAFETELAKISLSSEELRDPEKTYNPLTLAELQKLAP- 222
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 315 evngkSFSWSNFTNEIMSTVNINiqneEEVVVYAPEYLTKLKPILTKYSPRDLQNLMSWRFIMDLVSSLSRNYKESRNAF 394
Cdd:cd08662  223 -----SIDWKAYLKALGPPADDP----DKVIVSQPEYLKKLDKLLASTPLRTLKNYLIWRLLDSLAPYLSKEFRDARFFY 293
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 395 RKALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKKAEEKAL 474
Cdd:cd08662  294 GKALSGQKEPEPRWKRCVELVNGALGEALGRLYVEKYFSEEAKADVEEMVENIKEAFKERLENLDWMDEETKKKALEKLD 373
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 475 AIKERIGYPDDIiSNENKLNNEYLELNYrEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAAVVNAFYSSGRNQIV 554
Cdd:cd08662  374 AMKVKIGYPDKW-RDYSALDIYYDDLNV-SDSYFENVLRLLRFETKRQLAKLGKPVDRTEWSMSPQTVNAYYNPSLNEIV 451
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 555 FPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSANNFKDQSQCMVYQYGNFSWDla 634
Cdd:cd08662  452 FPAGILQPPFFDPDAPDALNYGGIGAVIGHEITHGFDDQGRQYDENGNLRNWWTNEDRKEFEERAQCLVDQYSNYEVP-- 529
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 635 GGQHLNGINTLGENIADNGGIGQAYRAYQNYVKKNGEEkLLPGLDLNHKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSP 714
Cdd:cd08662  530 PGLHVNGKLTLGENIADNGGLRLAYRAYKKWLKENGPE-LPGLEGFTPEQLFFLSFAQVWCSKYRPEALRQLLLTDPHSP 608
                        650       660       670
                 ....*....|....*....|....*....|....
gi 575402983 715 GNFRIIGTLQNSAEFADAFHCRKNSYMNPERKCR 748
Cdd:cd08662  609 GKFRVNGPLSNSPEFAEAFNCPPGSPMNPEKKCR 642
 
Name Accession Description Interval E-value
M13 cd08662
Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of ...
77-748 0e+00

Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of metallopeptidases includes neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11), endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), erythrocyte surface antigen KELL (ECE-3), phosphate-regulating gene on the X chromosome (PHEX), soluble secreted endopeptidase (SEP), and damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE). Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the active site's S2' subsite allowing substrate specificity. NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P, enkephalins, cholecystokinin, neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD). ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyzes bradykinin, substance P, neurotensin, and Abeta. Endothelin-1 overproduction has been implicated in various diseases including stroke, asthma, hypertension, and cardiac and renal failure. Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A. PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets. ECEL1 is a brain metalloprotease which plays a critical role in the nervous regulation of the respiratory system, while DINE is abundantly expressed in the hypothalamus and its expression responds to nerve injury. A majority of these M13 proteases are prime therapeutic targets for selective inhibition.


Pssm-ID: 341056 [Multi-domain]  Cd Length: 642  Bit Score: 780.01  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  77 VEPCTDFFKYACGGWLKRNVIPETSSRYSNFDILRDELEVILKDVLQEP--KTEDIVAVQKAKTLYRSCINESAIDSRGG 154
Cdd:cd08662    1 VDPCDDFYQYACGNWLKNHPIPADKSSWGSFSELQDRNEEQLREILEEAasSAADSSAEQKAKDFYKSCMDEEAIEKLGL 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 155 QPLLKLLPDIYGWPVASDNWDQTYgtswtaeksiAQLNSKYGKKVLINFFVGTDDKNSTQHIIHFDQPRLGLPSRDYYEc 234
Cdd:cd08662   81 KPLKPLLDKIGGLPSLDDLAAELL----------LALLRRLGVSLLFGLGVSPDPKNSSRNILYLGQPGLGLPDRDYYL- 149
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 235 TGIYKEACTAYVDFMISVARLirqeqsLPIDENQLSLEMNKVMELEKEIANATTKPEDRNDPMLLYNKMTLAKLQNNFSl 314
Cdd:cd08662  150 DEENAEIREAYKKYIAKLLEL------LGADEEEAEKLAEDVLAFETELAKISLSSEELRDPEKTYNPLTLAELQKLAP- 222
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 315 evngkSFSWSNFTNEIMSTVNINiqneEEVVVYAPEYLTKLKPILTKYSPRDLQNLMSWRFIMDLVSSLSRNYKESRNAF 394
Cdd:cd08662  223 -----SIDWKAYLKALGPPADDP----DKVIVSQPEYLKKLDKLLASTPLRTLKNYLIWRLLDSLAPYLSKEFRDARFFY 293
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 395 RKALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKKAEEKAL 474
Cdd:cd08662  294 GKALSGQKEPEPRWKRCVELVNGALGEALGRLYVEKYFSEEAKADVEEMVENIKEAFKERLENLDWMDEETKKKALEKLD 373
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 475 AIKERIGYPDDIiSNENKLNNEYLELNYrEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAAVVNAFYSSGRNQIV 554
Cdd:cd08662  374 AMKVKIGYPDKW-RDYSALDIYYDDLNV-SDSYFENVLRLLRFETKRQLAKLGKPVDRTEWSMSPQTVNAYYNPSLNEIV 451
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 555 FPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSANNFKDQSQCMVYQYGNFSWDla 634
Cdd:cd08662  452 FPAGILQPPFFDPDAPDALNYGGIGAVIGHEITHGFDDQGRQYDENGNLRNWWTNEDRKEFEERAQCLVDQYSNYEVP-- 529
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 635 GGQHLNGINTLGENIADNGGIGQAYRAYQNYVKKNGEEkLLPGLDLNHKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSP 714
Cdd:cd08662  530 PGLHVNGKLTLGENIADNGGLRLAYRAYKKWLKENGPE-LPGLEGFTPEQLFFLSFAQVWCSKYRPEALRQLLLTDPHSP 608
                        650       660       670
                 ....*....|....*....|....*....|....
gi 575402983 715 GNFRIIGTLQNSAEFADAFHCRKNSYMNPERKCR 748
Cdd:cd08662  609 GKFRVNGPLSNSPEFAEAFNCPPGSPMNPEKKCR 642
PepO COG3590
Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];
70-750 0e+00

Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];


Pssm-ID: 442809 [Multi-domain]  Cd Length: 674  Bit Score: 613.31  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  70 IQNMDASVEPCTDFFKYACGGWLKRNVIPETSSRYSNFDILRDELEVILKDVLQE----PKTEDIVAvQKAKTLYRSCIN 145
Cdd:COG3590   30 LANMDTSVRPGDDFYRYVNGGWLKTTPIPADRSRWGSFNELRERNEARLRAILEEaaaaPAAAGSDE-QKIGDLYASFMD 108
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 146 ESAIDSRGGQPLLKLLPDIygwpvasdnwdqtygtswTAEKSIAQLNS------KYGKKVLINFFVGTDDKNSTQHIIHF 219
Cdd:COG3590  109 EAAIEALGLAPLKPDLARI------------------DAIKDKADLAAllaalhRAGVGGLFGFGVDADLKNSTRYIAYL 170
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 220 DQPRLGLPSRDYY-ECTGIYKEACTAYVDFMISVARLirqeqsLPIDENQLSLEMNKVMELEKEIANATTKPEDRNDPML 298
Cdd:COG3590  171 GQGGLGLPDRDYYlKDDEKSAEIRAAYVAHVAKMLEL------AGYDEADAAAAAEAVLALETALAKAHWSRVELRDPEK 244
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 299 LYNKMTLAKLQNNFslevngKSFSWSNFTNEImstvniNIQNEEEVVVYAPEYLTKLKPILTKYSPRDLQNLMSWRFIMD 378
Cdd:COG3590  245 TYNPMTVAELAKLA------PGFDWDAYLKAL------GLPAVDEVIVGQPSFFKALDKLLASTPLEDWKAYLRWHLLDS 312
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 379 LVSSLSRNYKESRNAFR-KALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDD 457
Cdd:COG3590  313 AAPYLSKAFVDANFDFYgKTLSGQKEQRPRWKRAVALVNGALGEALGQLYVERYFPPEAKARMEELVANLRAAYRERIEN 392
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 458 LTWMDAETKKKAEEKALAIKERIGYPDDIIsnenklnnEYLELNYREDEYFENIIQNLKFSQSKQLKKLREKVDKDEWIS 537
Cdd:COG3590  393 LDWMSPETKAKALEKLAAFTPKIGYPDKWR--------DYSGLEIKRDDLVGNVLRASAFEYQRELAKLGKPVDRTEWGM 464
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 538 GAAVVNAFYSSGRNQIVFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSANNFKD 617
Cdd:COG3590  465 TPQTVNAYYNPTMNEIVFPAAILQPPFFDPKADDAVNYGGIGAVIGHEITHGFDDQGSQFDGDGNLRNWWTPEDRAAFEA 544
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 618 QSQCMVYQYGNFSWdlAGGQHLNGINTLGENIADNGGIGQAYRAYQNYVKKNGEEKL--LPGLdlnhkQLFFLNFAQVWC 695
Cdd:COG3590  545 RTKKLVAQYDAYEP--LPGLHVNGKLTLGENIADLGGLSIAYDAYKLSLKGKEAPVIdgFTGD-----QRFFLGWAQVWR 617
                        650       660       670       680       690
                 ....*....|....*....|....*....|....*....|....*....|....*..
gi 575402983 696 GTYRPEYAVNSIKTDVHSPGNFRIIGTLQNSAEFADAFHCRKNS--YMNPERKCRVW 750
Cdd:COG3590  618 SKARDEALRQRLATDPHSPGEFRVNGPVRNLDAFYEAFDVKPGDkmYLAPEDRVRIW 674
Peptidase_M13_N pfam05649
Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of ...
79-483 3.03e-140

Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of organizms including mammals and bacteria. In mammals they participate in processes such as cardiovascular development, blood-pressure regulation, nervous control of respiration, and regulation of the function of neuropeptides in the central nervous system. In bacteria they may be used for digestion of milk.


Pssm-ID: 461703  Cd Length: 382  Bit Score: 417.47  E-value: 3.03e-140
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983   79 PCTDFFKYACGGWLKRNVIPETSSRYSNFDILRDELEVILKDVLQEP--KTEDIVAVQKAKTLYRSCINESAIDSRGGQP 156
Cdd:pfam05649   1 PCDDFYQYACGGWLKNHPIPADKSSWGTFDELRERNEKQLREILEEAaaSESDPGAVEKAKDLYKSCMDTDAIEKLGLKP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  157 LLKLLPDIYGWPVASDNWDqtygtsWTaeKSIAQLnSKYGKKVLINFFVGTDDKNSTQHIIHFDQPRLGLPSRDYYECTG 236
Cdd:pfam05649  81 LKPLLDEIGGPLANKDKFD------LL--ETLAKL-RRYGVDSLFGFGVGPDDKNSSRNILYLDQPGLGLPDRDYYLKDR 151
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  237 --IYKEACTAYVDFMISVARLIRqeqslpiDENQLSLEMNKVMELEKEIANATTKPEDRNDPMLLYNKMTLAKLQNNFsl 314
Cdd:pfam05649 152 deKSAEIREAYKAYIAKLLTLLG-------ASEEAAALAEEVLAFETKLAKASLSREERRDPEKTYNPMTLAELQKLA-- 222
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  315 evngKSFSWSNFtneiMSTVNINIQNEEEVVVYAPEYLTKLKPILTKYSPRDLQNLMSWRFIMDLVSSLSRNYKESRNAF 394
Cdd:pfam05649 223 ----PGIDWKAY----LNAAGLPDVPSDEVIVSQPEYLKALSKLLAETPLRTLKNYLIWRLVRSLAPYLSDEFRDANFEF 294
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  395 RKALYGTTSEtATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKKAEEKAL 474
Cdd:pfam05649 295 YGTLSGTKQR-PRWKRCVSLVNGLLGEALGRLYVKKYFPEEAKARVEELVENIKEAFRERLDELDWMDEETKKKALEKLD 373

                  ....*....
gi 575402983  475 AIKERIGYP 483
Cdd:pfam05649 374 AMTVKIGYP 382
 
Name Accession Description Interval E-value
M13 cd08662
Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of ...
77-748 0e+00

Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of metallopeptidases includes neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11), endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), erythrocyte surface antigen KELL (ECE-3), phosphate-regulating gene on the X chromosome (PHEX), soluble secreted endopeptidase (SEP), and damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE). Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the active site's S2' subsite allowing substrate specificity. NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P, enkephalins, cholecystokinin, neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD). ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyzes bradykinin, substance P, neurotensin, and Abeta. Endothelin-1 overproduction has been implicated in various diseases including stroke, asthma, hypertension, and cardiac and renal failure. Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A. PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets. ECEL1 is a brain metalloprotease which plays a critical role in the nervous regulation of the respiratory system, while DINE is abundantly expressed in the hypothalamus and its expression responds to nerve injury. A majority of these M13 proteases are prime therapeutic targets for selective inhibition.


Pssm-ID: 341056 [Multi-domain]  Cd Length: 642  Bit Score: 780.01  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  77 VEPCTDFFKYACGGWLKRNVIPETSSRYSNFDILRDELEVILKDVLQEP--KTEDIVAVQKAKTLYRSCINESAIDSRGG 154
Cdd:cd08662    1 VDPCDDFYQYACGNWLKNHPIPADKSSWGSFSELQDRNEEQLREILEEAasSAADSSAEQKAKDFYKSCMDEEAIEKLGL 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 155 QPLLKLLPDIYGWPVASDNWDQTYgtswtaeksiAQLNSKYGKKVLINFFVGTDDKNSTQHIIHFDQPRLGLPSRDYYEc 234
Cdd:cd08662   81 KPLKPLLDKIGGLPSLDDLAAELL----------LALLRRLGVSLLFGLGVSPDPKNSSRNILYLGQPGLGLPDRDYYL- 149
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 235 TGIYKEACTAYVDFMISVARLirqeqsLPIDENQLSLEMNKVMELEKEIANATTKPEDRNDPMLLYNKMTLAKLQNNFSl 314
Cdd:cd08662  150 DEENAEIREAYKKYIAKLLEL------LGADEEEAEKLAEDVLAFETELAKISLSSEELRDPEKTYNPLTLAELQKLAP- 222
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 315 evngkSFSWSNFTNEIMSTVNINiqneEEVVVYAPEYLTKLKPILTKYSPRDLQNLMSWRFIMDLVSSLSRNYKESRNAF 394
Cdd:cd08662  223 -----SIDWKAYLKALGPPADDP----DKVIVSQPEYLKKLDKLLASTPLRTLKNYLIWRLLDSLAPYLSKEFRDARFFY 293
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 395 RKALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKKAEEKAL 474
Cdd:cd08662  294 GKALSGQKEPEPRWKRCVELVNGALGEALGRLYVEKYFSEEAKADVEEMVENIKEAFKERLENLDWMDEETKKKALEKLD 373
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 475 AIKERIGYPDDIiSNENKLNNEYLELNYrEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAAVVNAFYSSGRNQIV 554
Cdd:cd08662  374 AMKVKIGYPDKW-RDYSALDIYYDDLNV-SDSYFENVLRLLRFETKRQLAKLGKPVDRTEWSMSPQTVNAYYNPSLNEIV 451
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 555 FPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSANNFKDQSQCMVYQYGNFSWDla 634
Cdd:cd08662  452 FPAGILQPPFFDPDAPDALNYGGIGAVIGHEITHGFDDQGRQYDENGNLRNWWTNEDRKEFEERAQCLVDQYSNYEVP-- 529
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 635 GGQHLNGINTLGENIADNGGIGQAYRAYQNYVKKNGEEkLLPGLDLNHKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSP 714
Cdd:cd08662  530 PGLHVNGKLTLGENIADNGGLRLAYRAYKKWLKENGPE-LPGLEGFTPEQLFFLSFAQVWCSKYRPEALRQLLLTDPHSP 608
                        650       660       670
                 ....*....|....*....|....*....|....
gi 575402983 715 GNFRIIGTLQNSAEFADAFHCRKNSYMNPERKCR 748
Cdd:cd08662  609 GKFRVNGPLSNSPEFAEAFNCPPGSPMNPEKKCR 642
PepO COG3590
Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];
70-750 0e+00

Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];


Pssm-ID: 442809 [Multi-domain]  Cd Length: 674  Bit Score: 613.31  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  70 IQNMDASVEPCTDFFKYACGGWLKRNVIPETSSRYSNFDILRDELEVILKDVLQE----PKTEDIVAvQKAKTLYRSCIN 145
Cdd:COG3590   30 LANMDTSVRPGDDFYRYVNGGWLKTTPIPADRSRWGSFNELRERNEARLRAILEEaaaaPAAAGSDE-QKIGDLYASFMD 108
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 146 ESAIDSRGGQPLLKLLPDIygwpvasdnwdqtygtswTAEKSIAQLNS------KYGKKVLINFFVGTDDKNSTQHIIHF 219
Cdd:COG3590  109 EAAIEALGLAPLKPDLARI------------------DAIKDKADLAAllaalhRAGVGGLFGFGVDADLKNSTRYIAYL 170
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 220 DQPRLGLPSRDYY-ECTGIYKEACTAYVDFMISVARLirqeqsLPIDENQLSLEMNKVMELEKEIANATTKPEDRNDPML 298
Cdd:COG3590  171 GQGGLGLPDRDYYlKDDEKSAEIRAAYVAHVAKMLEL------AGYDEADAAAAAEAVLALETALAKAHWSRVELRDPEK 244
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 299 LYNKMTLAKLQNNFslevngKSFSWSNFTNEImstvniNIQNEEEVVVYAPEYLTKLKPILTKYSPRDLQNLMSWRFIMD 378
Cdd:COG3590  245 TYNPMTVAELAKLA------PGFDWDAYLKAL------GLPAVDEVIVGQPSFFKALDKLLASTPLEDWKAYLRWHLLDS 312
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 379 LVSSLSRNYKESRNAFR-KALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDD 457
Cdd:COG3590  313 AAPYLSKAFVDANFDFYgKTLSGQKEQRPRWKRAVALVNGALGEALGQLYVERYFPPEAKARMEELVANLRAAYRERIEN 392
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 458 LTWMDAETKKKAEEKALAIKERIGYPDDIIsnenklnnEYLELNYREDEYFENIIQNLKFSQSKQLKKLREKVDKDEWIS 537
Cdd:COG3590  393 LDWMSPETKAKALEKLAAFTPKIGYPDKWR--------DYSGLEIKRDDLVGNVLRASAFEYQRELAKLGKPVDRTEWGM 464
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 538 GAAVVNAFYSSGRNQIVFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSANNFKD 617
Cdd:COG3590  465 TPQTVNAYYNPTMNEIVFPAAILQPPFFDPKADDAVNYGGIGAVIGHEITHGFDDQGSQFDGDGNLRNWWTPEDRAAFEA 544
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983 618 QSQCMVYQYGNFSWdlAGGQHLNGINTLGENIADNGGIGQAYRAYQNYVKKNGEEKL--LPGLdlnhkQLFFLNFAQVWC 695
Cdd:COG3590  545 RTKKLVAQYDAYEP--LPGLHVNGKLTLGENIADLGGLSIAYDAYKLSLKGKEAPVIdgFTGD-----QRFFLGWAQVWR 617
                        650       660       670       680       690
                 ....*....|....*....|....*....|....*....|....*....|....*..
gi 575402983 696 GTYRPEYAVNSIKTDVHSPGNFRIIGTLQNSAEFADAFHCRKNS--YMNPERKCRVW 750
Cdd:COG3590  618 SKARDEALRQRLATDPHSPGEFRVNGPVRNLDAFYEAFDVKPGDkmYLAPEDRVRIW 674
Peptidase_M13_N pfam05649
Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of ...
79-483 3.03e-140

Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of organizms including mammals and bacteria. In mammals they participate in processes such as cardiovascular development, blood-pressure regulation, nervous control of respiration, and regulation of the function of neuropeptides in the central nervous system. In bacteria they may be used for digestion of milk.


Pssm-ID: 461703  Cd Length: 382  Bit Score: 417.47  E-value: 3.03e-140
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983   79 PCTDFFKYACGGWLKRNVIPETSSRYSNFDILRDELEVILKDVLQEP--KTEDIVAVQKAKTLYRSCINESAIDSRGGQP 156
Cdd:pfam05649   1 PCDDFYQYACGGWLKNHPIPADKSSWGTFDELRERNEKQLREILEEAaaSESDPGAVEKAKDLYKSCMDTDAIEKLGLKP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  157 LLKLLPDIYGWPVASDNWDqtygtsWTaeKSIAQLnSKYGKKVLINFFVGTDDKNSTQHIIHFDQPRLGLPSRDYYECTG 236
Cdd:pfam05649  81 LKPLLDEIGGPLANKDKFD------LL--ETLAKL-RRYGVDSLFGFGVGPDDKNSSRNILYLDQPGLGLPDRDYYLKDR 151
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  237 --IYKEACTAYVDFMISVARLIRqeqslpiDENQLSLEMNKVMELEKEIANATTKPEDRNDPMLLYNKMTLAKLQNNFsl 314
Cdd:pfam05649 152 deKSAEIREAYKAYIAKLLTLLG-------ASEEAAALAEEVLAFETKLAKASLSREERRDPEKTYNPMTLAELQKLA-- 222
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  315 evngKSFSWSNFtneiMSTVNINIQNEEEVVVYAPEYLTKLKPILTKYSPRDLQNLMSWRFIMDLVSSLSRNYKESRNAF 394
Cdd:pfam05649 223 ----PGIDWKAY----LNAAGLPDVPSDEVIVSQPEYLKALSKLLAETPLRTLKNYLIWRLVRSLAPYLSDEFRDANFEF 294
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  395 RKALYGTTSEtATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKKAEEKAL 474
Cdd:pfam05649 295 YGTLSGTKQR-PRWKRCVSLVNGLLGEALGRLYVKKYFPEEAKARVEELVENIKEAFRERLDELDWMDEETKKKALEKLD 373

                  ....*....
gi 575402983  475 AIKERIGYP 483
Cdd:pfam05649 374 AMTVKIGYP 382
Peptidase_M13 pfam01431
Peptidase family M13; Mammalian enzymes are typically type-II membrane anchored enzymes which ...
543-749 1.35e-80

Peptidase family M13; Mammalian enzymes are typically type-II membrane anchored enzymes which are known, or believed to activate or inactivate oligopeptide (pro)-hormones such as opioid peptides. The family also contains a bacterial member believed to be involved with milk protein cleavage.


Pssm-ID: 279739 [Multi-domain]  Cd Length: 205  Bit Score: 256.19  E-value: 1.35e-80
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  543 NAFYSSGRNQIVFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSANNFKDQSQCM 622
Cdd:pfam01431   1 NAYYQPNRNEIVFPAAILQPPFFDPNYPRAVNYGGIGNVIAHEITHGFDDQGAQFDKDGNLRSWWTDEDAEEFKDRAQCL 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 575402983  623 VYQYGNFSwDLAGGQHLNGINTLGENIADNGGIGQAYRAYQNyvKKNGEEKLLPGLD-LNHKQLFFLNFAQVWCGTYRPE 701
Cdd:pfam01431  81 IEQYSEYT-PPDGTKCANGTLTLGENIADLGGLTIALRAYKK--LLSANETVLPGFEnLTPDQLFFRGAAQIWCMKQSPA 157
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|....*...
gi 575402983  702 YAVNSIKTDVHSPGNFRIIGTLQNSAEFADAFHCRKNSYMNPERKCRV 749
Cdd:pfam01431 158 EVLRQLLVDPHSPPEFRVNGVMSNMPAFYEAFNCPEGDKMNPEPRCRL 205
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
543-596 2.07e-05

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 44.01  E-value: 2.07e-05
                         10        20        30        40        50
                 ....*....|....*....|....*....|....*....|....*....|....
gi 575402983 543 NAFYSSGRNQIVFPAGILQppffsaqqsnslNYGGIGMVIGHEITHGFDDNGRN 596
Cdd:cd09594   42 YNAMWIPSTNIFYGAGILD------------TLSGTIDVLAHELTHAFTGQFSN 83
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH